EPH74 Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk **Reduction in a Medicare Population**

Shivani Aggarwal¹, Jonathan Watts¹, Na An², David Goldfarb³, Sushma Reddy Vadyala², Puneet Budhiraja²

¹Landmark Science, Inc., Los Angeles, CA, USA, ²Humbi LLC, Nashville, TN, USA, ³Landmark Science, Inc., New York, NY, USA

Background and Rationale

Methods

- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) have been approved for Type 2 diabetes (T2D), and obesity.
- More recently, in March 2024, Wegovy ® (semaglutide) became the first GLP-1 RA approved for cardiovascular risk reduction, followed by Ozempic® (semaglutide) approval in January 2025 for reduction in the risk of worsening kidney disease and cardiovascular death in adults with T2D and chronic kidney disease.
- However, GLP-1 RA trends across these indications have not been well characterized among Medicare beneficiaries. Objective: to describe clinical characteristics, treatment patterns, and outcomes of GLP-1 RA initiators in the US Medicare 100% Fee-for-Service (FFS) population.



Poster

Study Design

- We conducted a retrospective observational cohort study of patients initiating GLP-1 RAs using the 100% Medicare FFS claims database.
- Data Source: This study uses data from the 100% Medicare FFS database and pharmacy data. The Medicare FFS is a traditional fee-for-service health plan with two parts: Part A [Hospital Insurance] and Part B [Medical Insurance]). Part B insurance contains information related to inpatient, outpatient, and office visits.



Eligibility Criteria

- All patients initiating GLP-1 RAs between January 01, 2018–June 30, 2024.
- At least 18 years of age at index date.
- At least 6 months of continuous health plan and pharmacy enrollment (Part A, Part, B, & Part D) prior to the index date. Outcomes

- Real-world overall survival (rwOS), defined as death in the follow-up period.
- Myocardial infarction (MI), defined as the presence of ICD-10-CM code of I21.XX for acute myocardial infarction in the follow-up period.
- Discontinuation was defined as a gap of >90 days between one claim/pharmacy fill date plus days supply and the subsequent fill date.

- described.
- Time to event analysis
- (censoring criteria).
- (censoring criteria).

Key Findings

- Median age of patients initiating GLP-1 RA was 69 (IQR: 65-74) and more than half were female (55.7%). 74.9% of patients were White (Table 1).
- Majority of specialty of the prescribing provider was primary care physician (53.7%), followed by nurse practitioners (18.4%).
- The majority of GLP-1 RA patients had T2D (87.8%) and 45.5% were obese/overweight. • Semaglutide (Ozempic, Rybelsus, Wegovy) increased yearly in the Medicare population and accounted for half the GLP-1 RAs initiated during the study period, with Ozempic and Rybelsus accounting for 53.8% and 11.4%, respectively, on or after 2022 (Figure 3). Wegovy was initiated predominantly from March 2024 onwards.
- The 3-year cumulative incidence of myocardial infarction (MI) was 9.5% (95% CI: 9.4–9.6%) (Figure 4a), with numerically varied by drug (Figure 4b).
- Overall survival at 3 years was 87.5% (95% CI: 87.4-87.6%) among GLP-1 RA initiators (Figure 5a), and numerically varied by generic drug (Figure 5b).

Limitations

- The study was descriptive and does not establish causal relationships between GLP-1 RA use, indications, and death and cardiovascular outcomes.
- The study population was limited to Medicare FFS beneficiaries and may not be representative of other populations (e.g., younger patients, Medicare Advantage).
- Cardiovascular outcomes were identified using administrative claims data, which may be subject to coding inaccuracies.
- Key variables such as BMI, lab values, or lifestyle factors were not available or had high missingness in claims.

Why is this Research Important

- GLP-1 RAs are medications used to treat Type 2 diabetes and help reduce heart and metabolic risks.
- Semaglutide use increased rapidly over the study period, becoming the most commonly used GLP-1 RA by 2023.
- While endocrinologists can prescribe GLP-1 medications, most patients received theirs from primary care doctors or nurse practitioners.
- This study tracked MI and overall survival over three years among Medicare patients taking GLP-1 medications, providing real-world benchmarks across all GLP-1 indications
- In this analysis, semaglutide and tirzepatide demonstrated a numerically greater reduction in death and MI compared to other GLP-1 receptor agonists. Further investigation is warranted to understand the factors contributing to these differences.



Scan here for e-poste



Analysis

Index date: date of GLP-1 RA initiation within study period. Baseline and clinical characteristics within 6 months prior to index date were

Utilization was described by generic drug over years.

Outcomes (rwOS, MI) were presented overall and by generic drug.


Patients indexed between 2018-2023 were included to allow for the opportunity of ≥ 6 months of follow-up.

rwOS: time from index date to earliest of date of death, or end of enrollment, discontinuation of any GLP-1 RA drug, or end of study period

MI: time from index date to earliest of MI, or date of death, end of enrollment, discontinuation of any GLP-1 RA drug, or end of study period


Additional censoring criteria for by-drug analysis included discontinuation of the specific generic, or date of switch to different generic drug.

Humbi Al




Age at GLP-1 RA initiation (years)	
Mean (STD)	
Median (Q1-Q3)	
Sex	
Male	
Female	
Unknown	
Race/ethnicity	
White	
Black	
Asian	
Hispanic	
Other/Unknown	
Region	
Midwest	
Northeast	
South	
West	
Specialty	
Primary care physician	
Nurse practitioner	
Endocrinologist	
Other	
Unknown	

Figure 2. Baseline Comorbidities



T2D = type 2 diabetes; CVA = cerebrovascular disease; MI = myocardial infarction; CHF = congestive heart failure; PVD = peripheral vascular disease; COPD = chronic obstructive pulmonary disease. *Moderate to severe renal disease. Baseline characteristics within the 6 months prior to index date are reported.



E-poster and supplementary materials Copies of this poster and supplementary materials obtained through the QR code or link are for personal use only and may not be reproduced without permission

Results

Funding

References

References are available upon request to the corresponding author: Shivani@landmarkscience.com This study was funded by Landmark Science,

Inc. and Humbi, LLC.

Science, Inc. SV, NA, and PB are employees of Humbi, LLC.

approvals on/after 2022

Months

Disclosures SA, JW, and DG are employees of or are contracted to Landmark